Hints and tips:
Related Special Reports
...Rivals AstraZeneca, Johnson & Johnson, Russia’s Sputnik V and new entrants such as Novavax make up the remainder of the market, which is forecast to double in value to $124bn next year....
...“The strategic decision was based on the competition for capital within Croda,” said Steve Foots, chief executive of the producer of lipids for BioNTech/Pfizer’s messenger RNA Covid vaccine....
...The AU will pay $6.75 a dose for the BioNTech/Pfizer vaccine and $10 for Johnson & Johnson’s, a single-dose product....
...After such strong reads from the first two releases (three if we count Russia’s Sputnik V), the disappointing AZN figures were perhaps bound to prompt downward pressure on the company’s shares....
...In August, Russia became the first country to approve a Covid-19 vaccine — named Sputnik V — for civilian use, but western experts cast doubt on its efficacy and safety....
...Britain’s AstraZeneca made $3bn in China sales last year, about 13 per cent of its global total while the US’ Pfizer made 7 per cent of its revenues in China last year, trailing only the US and Japan....
...SpringWorks launched on Monday after securing $103m of funds from investors including Bain Capital, the private equity group, Orbimed, the biotech investor, and Pfizer, which has taken a minority stake in...
...Among the deals is Toshiba’s $18bn sale of its memory chip business to a consortium led by Bain Capital, which was signed on Thursday....
...He agreed with William Bain, a Labour member of the committee, that under Takeover Panel rules any commitments by Pfizer would be binding for only one year....
...The possibility of a Pfizer/AstraZeneca deal still has the politicians talking (the chief executives of both were hauled before the UK parliament this week)....
...beyondbrics India v China: a new race in biopharmaceuticals, beyondbrics...
...At least three private equity groups – Bain, Blackstone and TH Lee – are believed to have entered advanced discussions over the sale of the remaining assets, but discussions have yet to be finalised and...
...Capsugel, a wholesale pill casings manufacturer acquired by KKR from Pfizer for $2.4bn in April, sold €325m of notes last week, which yielded 9.875 per cent on issuance....
...Never in the sector’s entire history has there been a period of stagnation, with very little growth likely for the next five or 10 years,” says Tim van Biesen, head of the Americas healthcare practice at Bain...
...Danish insulin producer Novo Nordisk fell 5.1 per cent to DKr511 after the worlds top drug-maker Pfizer agreed a deal to sell insulin to Indian group Biocon....
...Pfizer, the largest US drugmaker by market value, inched down 0.7 per cent to $14.54 as the stock being removed from the “conviction buy” list at Goldman Sachs....
...“There’s a lot of talk about the patent cliff,” says Nils Behnke, a partner with Bain, the consultancy. “The problem could maybe have been solved 10 years ago. But now there is going to be a gap.”...
...Last week’s US jobs report has knocked investor confidence, and those predicting a V-shaped recovery are finding it harder to justify their positions....
...Vaccines now contribute up to 20 per cent of the revenues of companies such as Merck and GSK, estimates Andy Pasternak, a partner of Bain & Co....
...This spurred groups such as Pfizer of the US and Roche of Switzerland to strike multi-billion-dollar deals during the first half of this year....
...Traders cited rumours of interest from financier Joao V Azevedo, who has close links with Portuguese starch maker Copam....
...Furthermore, as Tim van Biesen, a partner at Bain, the management consultancy, argues, “the generic drugs cabinet meets the needs of the vast majority of patients in the developing world”....
...Jamail has been hired by Bain and THL to fight Clear Channel’s corner. In Pennzoil v....
...Zoom: The Global Race to Fuel the Car of the Future By Iain Carson and Vijay V....
...Kindler, Chairman and CEO, Pfizer Inc., USA Klaus Kleinfeld, President and CEO, Siemens AG, Germany Mustafa V....
International Edition